Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1676757rdf:typepubmed:Citationlld:pubmed
pubmed-article:1676757lifeskim:mentionsumls-concept:C0031330lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0927232lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C1948023lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1676757lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:1676757pubmed:issue7lld:pubmed
pubmed-article:1676757pubmed:dateCreated1991-8-14lld:pubmed
pubmed-article:1676757pubmed:abstractTextIn a continuous search for a novel cerebroprotective drug with a central nervous system (CNS) stimulating activity, a series of 1-(acylamino)-7-hydroxyindan derivatives has been synthesized and tested for its dual activities. The cerebroprotective activities of the compounds in this series were evaluated in terms of their effect on the survival of mice in hypoxic conditions (210 mmHg), and their CNS stimulating activities were examined by evaluating their promotional effects on the recovery from coma induced by cerebral concussion in mice. Several compounds prolonged the survival of mice in the hypoxic conditions at a dose of 30 mg/kg po. Four compounds in this series showed the CNS-stimulating effect at the same dose. Among them, 7-hydroxy-1-[4-(3-methoxyphenyl)-1-piperazinyl]acetyl]amino]-2,2,4, 6-tetramethylindan (18, OPC-14117), which was active in the two tests with no side effect up to 500 mg/kg po daily for 2 weeks of administration to rats, was selected for preclinical investigations.lld:pubmed
pubmed-article:1676757pubmed:languageenglld:pubmed
pubmed-article:1676757pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1676757pubmed:citationSubsetIMlld:pubmed
pubmed-article:1676757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1676757pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1676757pubmed:statusMEDLINElld:pubmed
pubmed-article:1676757pubmed:monthJullld:pubmed
pubmed-article:1676757pubmed:issn0022-2623lld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:TanakaTTlld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:HiroseTTlld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:SakuraiYYlld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:KikuchiTTlld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:TottoriKKlld:pubmed
pubmed-article:1676757pubmed:authorpubmed-author:OshiroYYlld:pubmed
pubmed-article:1676757pubmed:issnTypePrintlld:pubmed
pubmed-article:1676757pubmed:volume34lld:pubmed
pubmed-article:1676757pubmed:ownerNLMlld:pubmed
pubmed-article:1676757pubmed:authorsCompleteYlld:pubmed
pubmed-article:1676757pubmed:pagination2014-23lld:pubmed
pubmed-article:1676757pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:meshHeadingpubmed-meshheading:1676757-...lld:pubmed
pubmed-article:1676757pubmed:year1991lld:pubmed
pubmed-article:1676757pubmed:articleTitleNovel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.lld:pubmed
pubmed-article:1676757pubmed:affiliationOtsuka Pharmaceutical Company Ltd. Third Institute of New Drug Research, Tokushima, Japan.lld:pubmed
pubmed-article:1676757pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:1676757lld:chembl